The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01041183

Enrollment

120

Registered

2009-12-31

Start date

2009-11-30

Completion date

Unknown

Last updated

2009-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Cholecystectomy, Nausea, Vomiting

Keywords

Oral plus IV ramosetron may be more effective than, IV ramosetron and oral ramosetron for the prophylaxis of, PONV after laparoscopic cholecystectomy

Brief summary

Patients undergoing general anesthesia for laparoscopic cholecystectomy have a high risk of postoperative nausea and vomiting (PONV). The investigators investigated the effect of oral and IV ramosetron on PONV prophylaxis after laparoscopic cholecystectomy.

Interventions

DRUGoral ramosetron

0.1 mg oral ramosetron (group II)

DRUGintravenous ramosetron

0.3 mg IV ramosetron (group I)

DRUGoral and IV ramosetron

0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

25 Years to 65 Years

Healthy volunteers

Inclusion criteria

* ASA I-II patients, 25-65 years, electivelaparoscopic cholecystectomy under general anesthesia

Exclusion criteria

* GI disease, pregnant or menstruating, history of motion sickness and/or postoperative emesis, antiemetics within 24 h before surgery

Design outcomes

Primary

Measure	Time frame
Incidence of PONV	postoperative 0-48 h

Countries

South Korea

Contacts

Primary ContactJung-Hee Ryu, Ph.D

jinaryu@lycos.co.kr82-31-787-7497

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026